This “Myopia - Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Myopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Myopia: Understanding
Myopia: Overview
Myopia, also known as nearsightedness, is a common vision condition in which distant objects appear blurry while close objects can be seen clearly. It occurs when the eye grows too long from front to back or when the cornea is too curved, causing light rays to focus in front of the retina instead of directly on it. Myopia often begins in childhood and tends to progress into the teenage years, especially in cases where there is a strong genetic predisposition or environmental factors such as prolonged near work and limited outdoor activity. As its global prevalence continues to rise, particularly among school-aged children, early diagnosis and management have become essential to prevent complications and preserve long-term visual health. In addition to its impact on vision clarity, high myopia can increase the risk of serious eye conditions such as retinal detachment, glaucoma, and myopic maculopathy. Advances in optical and pharmacological treatments, including specialized lenses and eye drops, are helping to slow myopia progression. Public health initiatives promoting outdoor activities and visual hygiene are also being explored as preventive strategies.
Myopia typically presents with blurred vision when viewing distant objects, leading to difficulty seeing things like road signs or classroom boards clearly. Common signs include squinting, eye strain, and headaches, especially after prolonged visual tasks. Many individuals also report trouble seeing in low light or at night. In children, behaviors such as sitting too close to screens, frequent eye rubbing, and declining academic or sports performance may indicate developing myopia. As the condition progresses, individuals may become increasingly dependent on corrective lenses. As myopia advances, frequent changes in prescription may be needed to maintain clear vision. Early detection through routine eye exams is crucial for timely intervention and management.
Myopia can be classified into different types based on its underlying cause and severity, which is crucial for effective management. Axial myopia, the most common form, results from an elongated eyeball, with each 1-mm increase in axial length causing a 3 diopter (D) shift. Meridional or myopic astigmatism involves differing curvatures along two axes, typically due to corneal shape rather than eyeball length. Lenticular myopia arises from changes in the lens, especially with aging. Myopia severity is typically graded as mild (-0.5 to -4 D), moderate (-4 to -8 D), and severe (greater than -8 D). High or pathological myopia, often exceeding -8 D, is associated with an increased risk of ocular complications such as retinal detachment, macular degeneration, and glaucoma. Understanding the specific type and degree of myopia can guide treatment decisions, including optical correction, pharmacologic interventions, or lifestyle modifications. Early and accurate classification also aids in monitoring progression and preventing long-term visual impairment.
The treatment of myopia includes both non-surgical and surgical approaches. Non-surgical methods such as spectacles and contact lenses are widely used to correct vision, with advancements like anti-reflective coatings and blue light filters enhancing comfort and eye protection. Contact lenses, including rigid gas-permeable and soft lenses, offer clear vision but may cause complications if not properly maintained. Surgical options like laser vision correction (LASIK, PRK, and SMILE) reshape the cornea to correct refractive errors, while phakic intraocular lenses (IOLs) and lens replacement surgeries are alternatives for patients unsuitable for corneal procedures. Each treatment requires careful assessment to minimize complications and optimize visual outcomes.
"Myopia - Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myopia pipeline landscape is provided which includes the disease overview and Myopia treatment guidelines. The assessment part of the report embraces, in depth Myopia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myopia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Myopia R&D. The therapies under development are focused on novel approaches to treat/improve Myopia.
Myopia Emerging Drugs Chapters
This segment of the Myopia report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Myopia Emerging Drugs
Myopia: Therapeutic Assessment
This segment of the report provides insights about the different Myopia drugs segregated based on following parameters that define the scope of the report.
Major Players in Myopia
The report covers around 10+ products under different phases of clinical development, like:
Myopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as:
Products have been categorized under various Molecule types, such as:
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Myopia: Pipeline Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Myopia therapeutic drugs key players involved in developing key drugs.
Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myopia drugs.
Myopia Report Insights
Current Treatment Scenario and Emerging Therapies:
This product will be delivered within 2 business days.
Myopia: Understanding
Myopia: Overview
Myopia, also known as nearsightedness, is a common vision condition in which distant objects appear blurry while close objects can be seen clearly. It occurs when the eye grows too long from front to back or when the cornea is too curved, causing light rays to focus in front of the retina instead of directly on it. Myopia often begins in childhood and tends to progress into the teenage years, especially in cases where there is a strong genetic predisposition or environmental factors such as prolonged near work and limited outdoor activity. As its global prevalence continues to rise, particularly among school-aged children, early diagnosis and management have become essential to prevent complications and preserve long-term visual health. In addition to its impact on vision clarity, high myopia can increase the risk of serious eye conditions such as retinal detachment, glaucoma, and myopic maculopathy. Advances in optical and pharmacological treatments, including specialized lenses and eye drops, are helping to slow myopia progression. Public health initiatives promoting outdoor activities and visual hygiene are also being explored as preventive strategies.
Myopia typically presents with blurred vision when viewing distant objects, leading to difficulty seeing things like road signs or classroom boards clearly. Common signs include squinting, eye strain, and headaches, especially after prolonged visual tasks. Many individuals also report trouble seeing in low light or at night. In children, behaviors such as sitting too close to screens, frequent eye rubbing, and declining academic or sports performance may indicate developing myopia. As the condition progresses, individuals may become increasingly dependent on corrective lenses. As myopia advances, frequent changes in prescription may be needed to maintain clear vision. Early detection through routine eye exams is crucial for timely intervention and management.
Myopia can be classified into different types based on its underlying cause and severity, which is crucial for effective management. Axial myopia, the most common form, results from an elongated eyeball, with each 1-mm increase in axial length causing a 3 diopter (D) shift. Meridional or myopic astigmatism involves differing curvatures along two axes, typically due to corneal shape rather than eyeball length. Lenticular myopia arises from changes in the lens, especially with aging. Myopia severity is typically graded as mild (-0.5 to -4 D), moderate (-4 to -8 D), and severe (greater than -8 D). High or pathological myopia, often exceeding -8 D, is associated with an increased risk of ocular complications such as retinal detachment, macular degeneration, and glaucoma. Understanding the specific type and degree of myopia can guide treatment decisions, including optical correction, pharmacologic interventions, or lifestyle modifications. Early and accurate classification also aids in monitoring progression and preventing long-term visual impairment.
The treatment of myopia includes both non-surgical and surgical approaches. Non-surgical methods such as spectacles and contact lenses are widely used to correct vision, with advancements like anti-reflective coatings and blue light filters enhancing comfort and eye protection. Contact lenses, including rigid gas-permeable and soft lenses, offer clear vision but may cause complications if not properly maintained. Surgical options like laser vision correction (LASIK, PRK, and SMILE) reshape the cornea to correct refractive errors, while phakic intraocular lenses (IOLs) and lens replacement surgeries are alternatives for patients unsuitable for corneal procedures. Each treatment requires careful assessment to minimize complications and optimize visual outcomes.
"Myopia - Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myopia pipeline landscape is provided which includes the disease overview and Myopia treatment guidelines. The assessment part of the report embraces, in depth Myopia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myopia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Myopia R&D. The therapies under development are focused on novel approaches to treat/improve Myopia.
Myopia Emerging Drugs Chapters
This segment of the Myopia report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Myopia Emerging Drugs
CBT-009: Cloudbreak Pharma
Atropine is a mydriatic agent, which clinically shows promising potential in treating progressive Myopia. Topical ophthalmic atropine sulfate has an extensive clinical history dating back several decades. Topical ophthalmic solution of 1% atropine sulfate has been approved worldwide for use in producing cycloplegia, mydriasis and in penalizing the healthy eye in treatment of amblyopia. CBT-009 is a novel ophthalmic formulation of atropine, which will substantially improve atropine stability in the formulation and ultimately product shelf life. Currently, the drug is in Phase III stage of its development for the treatment of Myopia.SHJ002: Sunhawk Vision Biotech, Inc.
SHJ002 is an investigational therapeutic being developed for the treatment of myopia, aimed at controlling the progression of axial elongation - a primary factor contributing to the condition. Designed as a topical formulation, SHJ002 targets key molecular pathways involved in scleral remodeling, potentially stabilizing the structural integrity of the eye. By addressing the biomechanical and biochemical changes that lead to myopic progression, SHJ002 offers a non-invasive approach with the potential to complement or enhance existing myopia management strategies such as optical correction and lifestyle modifications. Currently, the drug is in Phase II stage of its development for the treatment of Myopia.IVMED 85: iVeena Delivery Systems, Inc.
IVMED-85 is a daily eye drop that strengthens scleral and corneal collagen crosslinks through LOX activation, potentially leading to improved refraction and a decrease in the rate of axial elongation. It works by enhancing the activity of lysyl oxidase (LOX), an enzyme critical for stabilizing extracellular matrix proteins like collagen and elastin. This biochemical reinforcement increases the biomechanical strength of ocular tissues, reducing progressive deformation of the eye. By targeting the structural integrity of the sclera, IVMED-85 aims to slow or halt myopic progression at its root cause. Currently, the drug is in Phase I/II clinical studies for the treatment of Myopia.Myopia: Therapeutic Assessment
This segment of the report provides insights about the different Myopia drugs segregated based on following parameters that define the scope of the report.
Major Players in Myopia
- There are approx. 8+ key companies which are developing the therapies for Myopia. The companies which have their Myopia drug candidates in the most advanced stage, i.e. Phase III include, Cloudbreak Pharma.
The report covers around 10+ products under different phases of clinical development, like:
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of:
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Myopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as:
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Products have been categorized under various Molecule types, such as:
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Myopia: Pipeline Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Myopia therapeutic drugs key players involved in developing key drugs.
Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myopia drugs.
Myopia Report Insights
- Myopia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Myopia drugs?
- How many Myopia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myopia?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Myopia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Myopia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Cloudbreak Pharma
- Sunhawk Vision Biotech, Inc.
- iVeena Delivery Systems, Inc.
- Stuart Therapeutics
- CBT-009
- SHJ002
- IVMED 85
- PolyCol
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive SummaryMyopia - Analytical PerspectiveMyopia Key CompaniesMyopia Key ProductsMyopia - Unmet NeedsMyopia - Market Drivers and BarriersMyopia - Future Perspectives and ConclusionMyopia Analyst ViewsMyopia Key CompaniesAppendix
Myopia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
CBT-009: Cloudbreak Pharma
Mid Stage Products (Phase II)
SHJ002: Sunhawk Vision Biotech, Inc.
Early Stage Products (Phase I/II)
IVMED 85: iVeena Delivery Systems, Inc.
Preclinical and Discovery Stage Products
Drug Name: Company Name
Inactive Products
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Cloudbreak Pharma
- Sunhawk Vision Biotech, Inc.
- iVeena Delivery Systems, Inc.
- Stuart Therapeutics
